{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:28:31Z","timestamp":1791980911434,"version":"4.4.0"},"reference-count":189,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Radiology, Mayo Clinic Rochester","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"https:\/\/ror.org\/02njr9k66","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>The dynamic field of radiopharmaceuticals is currently experiencing an explosion of growth due in part to excitement over the emerging field of theranostics (therapy and diagnostics). Radiopharmaceuticals use physiological targeting methods to deliver radionuclides with medically relevant decay properties to disease biomarkers for diagnosis and treatment, offering opportunities for early disease imaging and radiation therapy treatment in disease pathologies that are inoperable or refractory to other forms of radiotherapy. Sustaining this rapidly growing field depends heavily on the continued design and production of novel, effective radiopharmaceuticals. Effective therapeutic radiopharmaceuticals cause complex and varied cellular responses, and to choose radionuclides that maximize therapeutic response, researchers must understand radiation biology. Cellular radiation response depends heavily on factors including linear energy transfer (LET), dose, dose rate, targeted location, direct or indirect energy deposition mechanisms, the broader cellular matrix, cellular stress signaling pathways, and endogenous radiation protection mechanisms. Because of the extensive application of low-LET external beam radiation on clinical cancer treatments, biological responses to low-LET form the basis of radiation biology and are generally considered transferable to high-LET radiopharmaceuticals. However, increased focus on high-LET, radiopharmaceutical therapy-specific radiation biology is motivated by differences between low- and high-LET radiation, external beam versus radiopharmaceutical therapy-induced biological response, and the observed varied clinical responses to radiopharmaceutical therapies. This review article summarizes historical understanding of low- and high-LET radiation responses within cells, with emphasis on radiopharmaceutical-specific responses when available, and discusses current gaps in understanding in the radiation biology of radiotheranostic pharmaceuticals.<\/jats:p>","DOI":"10.3390\/ph19040591","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T07:25:12Z","timestamp":1775633112000},"page":"591","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Radiation Biology of Radiopharmaceuticals: Beyond External Beam Radiation Therapy"],"prefix":"10.3390","volume":"19","author":[{"given":"Aeli P.","family":"Olson","sequence":"first","affiliation":[{"name":"Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3399-7228","authenticated-orcid":false,"given":"Jonathan W.","family":"Engle","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, University of Wisconsin, Madison, WI 53705, USA"},{"name":"Department of Radiology, University of Wisconsin, Madison, WI 53705, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2332-5305","authenticated-orcid":false,"given":"Mukesh K.","family":"Pandey","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA"},{"name":"Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN 55905, USA"},{"name":"Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Bodei, L., Lewis, J.S., and Zeglis, B.M. (2023). Radiopharmaceutical Therapy, Springer Nature.","DOI":"10.1007\/978-3-031-39005-0"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3109\/02841869509127236","article-title":"A Glance at the History of Nuclear Medicine","volume":"34","author":"Carlsson","year":"1995","journal-title":"Acta Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/00004032-199511000-00004","article-title":"Uses of Therapeutic X Rays in Medicine","volume":"69","author":"Orton","year":"1995","journal-title":"Health Phys."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Baatout, S. (2023). Radiobiology Textbook, Springer International Publishing.","DOI":"10.1007\/978-3-031-18810-7"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2967\/jnumed.118.220665","article-title":"Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine","volume":"61","author":"Solnes","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_6","unstructured":"Krane, K.S. (1988). Introductory Nuclear Physics, John Wiley & Sons, Ltd."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/09553000400017663","article-title":"The Amazing World of Auger Electrons","volume":"80","author":"Kassis","year":"2004","journal-title":"Int. J. Radiat. Biol."},{"key":"ref_8","unstructured":"Knoll, G.F. (1979). Radiation Detection and Measurement, John Wiley & Sons, Inc."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Cherry, S.R., Sorenson, J.A., and Phelps, M.E. (2012). Physics of Nuclear Medicine, Saunders. [4th ed.].","DOI":"10.1016\/B978-1-4160-5198-5.00001-0"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0039-6028(75)90306-4","article-title":"The Auger Effect","volume":"48","author":"Auger","year":"1975","journal-title":"Surf. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2174\/157016310793360657","article-title":"Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy","volume":"7","author":"Cornelissen","year":"2010","journal-title":"Curr. Drug Discov. Technol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Powsner, R.A., Palmer, M.R., and Powsner, E.R. (2022). Essentials of Nuclear Medicine Physics, Instrumentation, and Radiation Biology, John Wiley & Sons Ltd.. [4th ed.].","DOI":"10.1002\/9781119621027"},{"key":"ref_13","unstructured":"Hubbell, J.H., and Seltzer, S.M. (2009). X-Ray Mass Attenuation Coefficients, National Institute of Standards and Technology (NIST)."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2307\/3578503","article-title":"On the Equivalent Dose for Auger Electron Emitters","volume":"134","author":"Howell","year":"1993","journal-title":"Radiat. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2307\/3578051","article-title":"The Question of Relative Biological Effectiveness and Quality Factor for Auger Emitters Incorporated into Proliferating Mammalian Cells","volume":"128","author":"Howell","year":"1991","journal-title":"Radiat. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41181-019-0075-2","article-title":"Auger Electrons for Cancer Therapy\u2014A Review","volume":"4","author":"Ku","year":"2019","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Pouget, J.-P., Lozza, C., Deshayes, E., Boudousq, V., and Navarro-Teulon, I. (2015). Introduction to Radiobiology of Targeted Radionuclide Therapy. Front. Med., 2.","DOI":"10.3389\/fmed.2015.00012"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Sadhukhan, R.K., Alam, M.J., and Synzynys, B.I. (2024, January 18\u201320). Contribution of Recoil Nucleus Energy to Total Absorbed Dose from Alpha and Beta Decay of Radionuclides Radium, Radon and Their Radioactive Progeny. Proceedings of the 2024 13th ICECE, Dhaka, Bangladesh.","DOI":"10.1109\/ICECE64886.2024.11025003"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.apradiso.2009.02.022","article-title":"Recoil Effect on Beta-Decaying In Vivo Generators, Interpreted for 103Pd\/103mRh","volume":"7\u20138","author":"Szucs","year":"2009","journal-title":"Appl. Radiat. Isot."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/jlcr.2906","article-title":"Recoil and Conversion Electron Implications to Be Taken into Account in the Design of Therapeutic Radiopharmaceuticals Utilizing In Vivo Generators","volume":"55","author":"Zeevaart","year":"2012","journal-title":"J. Label. Comp. Radiopharm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"100004","DOI":"10.1016\/j.craph.2025.100004","article-title":"Open Problems for the Preparation and Quality Control of Ac-225 Radiopharmaceuticals","volume":"19","author":"Crudo","year":"2026","journal-title":"Curr. Radiopharm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/B978-0-12-822960-6.00137-X","article-title":"Basics of Radiobiology","volume":"1","author":"Pouget","year":"2022","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.semradonc.2020.07.002","article-title":"The Radiobiology of Radiopharmaceuticals","volume":"31","author":"Morris","year":"2021","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1089\/ars.2015.6309","article-title":"Localized Irradiation of Cell Membrane by Auger Electrons Is Cytotoxic Through Oxidative Stress-Mediated Nontargeted Effects","volume":"25","author":"Paillas","year":"2016","journal-title":"Antioxid. Redox Signal."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1089\/ars.2017.7267","article-title":"Targeted and Off-Target (Bystander and Abscopal) Effects of Radiation Therapy: Redox Mechanisms and Risk\/Benefit Analysis","volume":"29","author":"Pouget","year":"2018","journal-title":"Antioxid. Redox Signal."},{"key":"ref_26","first-page":"283","article-title":"Abscopal Effect Following Radiation Monotherapy in Breast Cancer: A Case Report","volume":"9","author":"Azami","year":"2018","journal-title":"Mol. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Brenneman, R.J., Sharifai, N., Fischer-Valuck, B., Hassanzadeh, C., Guzelian, J., Chrisinger, J.S.A., Michalski, J.M., Oppelt, P., and Baumann, B.C. (2019). Abscopal Effect Following Proton Beam Radiotherapy in a Patient with Inoperable Metastatic Retroperitoneal Sarcoma. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00922"},{"key":"ref_28","first-page":"e2238","article-title":"Abscopal Effect in a Stage IV Melanoma Patient Who Progressed on Pembrolizumab","volume":"10","author":"Tsui","year":"2018","journal-title":"Cureus"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.currproblcancer.2015.10.001","article-title":"Systematic Review of Case Reports on the Abscopal Effect","volume":"40","author":"Abuodeh","year":"2016","journal-title":"Curr. Probl. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.freeradbiomed.2016.12.008","article-title":"Radiation-Induced Clustered DNA Lesions: Repair and Mutagenesis","volume":"107","author":"Sage","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1667\/0033-7587(2002)157[0589:FOMDBI]2.0.CO;2","article-title":"Formation of Modified DNA Bases in Cells Exposed Either to Gamma Radiation or to High-LET Particles","volume":"157","author":"Pouget","year":"2002","journal-title":"Radiat. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/sj.bjc.6601729","article-title":"Repair of Radiation Damage to DNA","volume":"90","author":"Willers","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Khazaei Monfared, Y., Heidari, P., Klempner, S.J., Mahmood, U., Parikh, A.R., Hong, T.S., Strickland, M.R., and Esfahani, S.A. (2023). DNA Damage by Radiopharmaceuticals and Mechanisms of Cellular Repair. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15122761"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1053\/j.semnuclmed.2008.05.002","article-title":"Therapeutic Radionuclides: Biophysical and Radiobiologic Principles","volume":"23","author":"Kassis","year":"2008","journal-title":"Semin. Nucl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0968-4328(99)00083-9","article-title":"Radiation Response of Cell Organelles","volume":"31","author":"Somosy","year":"2000","journal-title":"Micron"},{"key":"ref_37","first-page":"7031","article-title":"Large Deletions in Mitochondrial DNA in Radiation-Associated Human Thyroid Tumors","volume":"62","author":"Rogounovitch","year":"2002","journal-title":"Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0026-895X(25)11455-7","article-title":"A Method for Assessing Damage to Mitochondrial DNA Caused by Radiation and Epichiorohydrin","volume":"27","author":"Singh","year":"1985","journal-title":"Mol. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1134\/S1022795409070114","article-title":"Reduction of the Number of Mutant Copies of Mitochondrial DNA in Tissues of Irradiated Mice in the Postradiation Period","volume":"45","author":"Gulyaeva","year":"2009","journal-title":"Russ. J. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.freeradbiomed.2013.07.024","article-title":"Effects of Ionizing Radiation on Mitochondria","volume":"65","author":"Kam","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/mc.2940060404","article-title":"Suppression of Radiation-Induced Neoplastic Transformation by Overexpression of Mitochondrial Superoxide Dismutase","volume":"6","author":"Oberley","year":"1992","journal-title":"Mol. Carcinog."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.4161\/cbt.8.20.9648","article-title":"Mitochondrial ROS and Radiation Induced Transformation in Mouse Embryonic Fibroblasts","volume":"8","author":"Du","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"ref_43","first-page":"5382","article-title":"Overexpression of Mitochondrial Manganese Superoxide Dismutase Protects against Radiation-Induced Cell Death in the Human Hepatocellular Carcinoma Cell Line HLE1","volume":"61","author":"Motoori","year":"2001","journal-title":"Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"7114","DOI":"10.3390\/ijms12107114","article-title":"Manganese Superoxide Dismutase: Guardian of the Powerhouse","volume":"12","author":"Holley","year":"2011","journal-title":"Int. J. Mol. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Pouget, J.-P., and Constanzo, J. (2021). Revisiting the Radiobiology of Targeted Alpha Therapy. Front. Med., 8.","DOI":"10.3389\/fmed.2021.692436"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/09553000701370878","article-title":"Analysis of Common Deletion (CD) and a Novel Deletion of Mitochondrial DNA Induced by Ionizing Radiation","volume":"83","author":"Wang","year":"2007","journal-title":"Int. J. Radiat. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.mito.2011.07.005","article-title":"Effects of X-Irradiation on Mitochondrial DNA Damage and Its Supercoiling Formation Change","volume":"11","author":"Zhou","year":"2011","journal-title":"Mitochondrion"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0968-4328(01)00007-5","article-title":"Bystander Effects Caused by Nonuniform Distributions of DNA-Incorporated 125I","volume":"33","author":"Howell","year":"2002","journal-title":"Micron"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.nucmedbio.2013.02.001","article-title":"Apoptosis and P53 Are Not Involved in the Anti-Tumor Efficacy of 125I-Labeled Monoclonal Antibodies Targeting the Cell Membrane","volume":"40","author":"Paillas","year":"2013","journal-title":"Nucl. Med. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/09553002.2021.1955999","article-title":"Rapid Communication: Insights into the Role of Extracellular Vesicles during Auger Radioimmunotherapy","volume":"99","author":"Karam","year":"2023","journal-title":"Int. J. Radiat. Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1667\/RR3567.1","article-title":"Inhibitory and Stimulatory Bystander Effects Are Differentially Induced by Iodine-125 and Iodine-123","volume":"165","author":"Kishikawa","year":"2006","journal-title":"Radiat. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"13765","DOI":"10.1073\/pnas.182209699","article-title":"Bystander Effect Produced by Radiolabeled Tumor Cells In Vivo","volume":"99","author":"Xue","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1667\/RR1658.1","article-title":"Propagation Distance of the \u03b1-Particle-Induced Bystander Effect: The role of nuclear traversal and gap junction communication","volume":"171","author":"Gaillard","year":"2009","journal-title":"Radiat. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1667\/0033-7587(2001)155[0335:FRIAGJ]2.0.CO;2","article-title":"Free Radical-Initiated and Gap Junction-Mediated Bystander Effect Due to Nonuniform Distribution of Incorporated Radioactivity in a Three-Dimensional Tissue Culture Model","volume":"155","author":"Bishayee","year":"2001","journal-title":"Radiat. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1211\/jpp.60.8.0002","article-title":"Radiation Quality-Dependent Bystander Effects Elicited by Targeted Radionuclides","volume":"60","author":"Boyd","year":"2008","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/sj.bjc.6604358","article-title":"Mitochondria-Dependent Signaling Pathway Are Involved in the Early Process of Radiation-Induced Bystander Effects","volume":"98","author":"Chen","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_57","first-page":"1007","article-title":"Radiation-Induced Biologic Bystander Effect Elicited In Vitro by Targeted Radiopharmaceuticals Labeled with \u03b1-, \u03b2-, and Auger Electron-Emitting Radionuclides","volume":"47","author":"Boyd","year":"2006","journal-title":"J. Nucl. Med."},{"key":"ref_58","first-page":"131","article-title":"Radiation and Chemotherapy Bystander Effects Induce Early Genomic Instability Events: Telomere Shortening and Bridge Formation Coupled with Mitochondrial Dysfunction","volume":"669","author":"Gorman","year":"2009","journal-title":"Mutat. Res. Fundam. Mol. Mech. Mutagen."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4775","DOI":"10.1158\/1078-0432.CCR-18-3295","article-title":"Drugs That Modify Cholesterol Metabolism Alter the P38\/JNK-Mediated Targetedand Nontargeted Response to Alpha and Auger Radioimmunotherapy","volume":"25","author":"Ladjohounlou","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s41181-025-00393-0","article-title":"Assessing the Radiation-Induced Bystander Effect in Radionuclide Therapy Using Targeted Radiopharmaceuticals","volume":"10","author":"Sharma","year":"2025","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_61","first-page":"91","article-title":"Genomic Instability after Targeted Irradiation of Human Lymphocytes: Evidence for Inter-Individual Differences under Bystander Conditions","volume":"688","author":"Kadhim","year":"2010","journal-title":"Mutat. Res. Fundam. Mol. Mech. Mutagen."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/978-3-030-38862-1_10","article-title":"Immunogenic Cell Death Driven by Radiation\u2014Impact on the Tumor Microenvironment","volume":"180","author":"Yamazaki","year":"2020","journal-title":"Cancer Res. Treat."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e28518","DOI":"10.4161\/onci.28518","article-title":"Radiation Fosters Dose-Dependent and Chemotherapy-Induced Immunogenic Cell Death","volume":"3","author":"Golden","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00262-020-02606-8","article-title":"Immune Checkpoint Inhibitors Reverse Tolerogenic Mechanisms Induced by Melanoma Targeted Radionuclide Therapy","volume":"69","author":"Rouanet","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Kerr, C.P., Grudzinski, J.J., Nguyen, T.P., Hernandez, R., Weichert, J.P., and Morris, Z.S. (2023). Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15010128"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/2326-6066.CIR-24-1191","article-title":"The Effects of Clinically Relevant Radionuclides on the Activation of a Type I Interferon Response Correlate with Radionuclide Half-Life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy","volume":"13","author":"Kerr","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijrobp.2020.04.023","article-title":"The Promise of Combining Radiation Therapy with Immunotherapy","volume":"108","author":"Jagodinsky","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1080\/028418601750444141","article-title":"Low-Energy Electron Emitters for Targeted Radiotherapy of Small Tumours","volume":"40","author":"Bernhardt","year":"2001","journal-title":"Acta Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/rpd\/13.1-4.249","article-title":"Electron Dosimetry for Radioimmunotherapy: Optimal Electron Energy","volume":"13","author":"Sastry","year":"1985","journal-title":"Radiat. Prot. Dosim."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Marion, J.B. (1974). The Effects of Nuclear Radiations. Energy in Perspective, Elsevier.","DOI":"10.1016\/B978-0-12-472275-0.50009-9"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3109\/02841869609104045","article-title":"Calculation of Equivalent Dose for Auger Electron Emitting Radionuclides Distributed in Human Organs","volume":"35","author":"Goddu","year":"1996","journal-title":"Acta Oncol."},{"key":"ref_72","unstructured":"Howell, R.W., Narra, V.R., Hou, D., Terrone, D.A., Harapanhalli, R., Sastry, K.S.R., and Rao, D.V. (1992). Relative Biological Effectiveness of Auger Emitters for Cell Inactivation: In Vitro Versus In Vivo, American Inst. of Physics, Inc."},{"key":"ref_73","unstructured":"Seltzer, S.M. (2008). NIST 7. NIST Electron and Positron Stopping Power of Materials, National Institute of Standards and Technology (NIST)."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","article-title":"177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy","volume":"57","author":"Baum","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0168-9002(03)01368-8","article-title":"GEANT4\u2014A Simulation Toolkit","volume":"506","author":"Agostinelli","year":"2003","journal-title":"Nucl. Instrum. Methods Phys. Res. A"},{"key":"ref_76","unstructured":"IAEA (2026, January 15). Live Chart of Nuclides: Nuclear Structure and Decay Data, Available online: https:\/\/www.nndc.bnl.gov\/nudat3\/."},{"key":"ref_77","unstructured":"Eckerman, K.F., and Endo, A. (2008). MIRD: Radionuclide Data and Decay Schemes, Society of Nuclear Medicine. [2nd ed.]."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.7150\/thno.15132","article-title":"Comparison between Three Promising \u03b2-Emitting Radionuclides, 67Cu, 47Sc and 161Tb, with Emphasis on Doses Delivered to Minimal Residual Disease","volume":"6","author":"Champion","year":"2016","journal-title":"Theranostics"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2967\/jnumed.115.170423","article-title":"Dose Deposits from 90Y, 177Lu, 111In, And 161Tb in Micrometastases of Various Sizes: Implications for Radiopharmaceutical Therapy","volume":"57","author":"Hindie","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40658-022-00495-7","article-title":"Active Bone Marrow S-Values for the Low-Energy Electron Emitter Terbium-161 Compared to S-Values for Lutetium-177 and Yttrium-90","volume":"9","author":"Hemmingsson","year":"2022","journal-title":"EJNMMI Phys."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2310\/7290.2010.00008","article-title":"Unconventional Nuclides for Radiopharmaceuticals","volume":"9","author":"Holland","year":"2010","journal-title":"Mol. Imaging"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1021\/acs.chemrev.8b00294","article-title":"Radioactive Main Group and Rare Earth Metals for Imaging and Therapy","volume":"119","author":"Kostelnik","year":"2019","journal-title":"Chem. Rev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[177Lu]Lu-DOTA-TATE plus Long-Acting Octreotide versus High-dose Long-Acting Octreotide for the Treatment of Newly Diagnosed, Advanced Grade 2\u20133, Well-Differentiated, Gastroenteropancreatic Neuroendocrine Tumours (NETTER-2): An Open-Label, Randomised, Phase 3 Study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1007\/s00259-024-06963-9","article-title":"EANM Expert Opinion: How Can Lessons from Radiobiology Be Applied to the Design of Clinical Trials? Part I: Back to the Basics of Absorbed Dose\u2013Response and Threshold Absorbed Doses","volume":"52","author":"Pouget","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Elgqvist, J., Frost, S., Pouget, J.-P., and Albertsson, P. (2014). The Potential and Hurdles of Targeted Alpha Therapy\u2014Clinical Trials and Beyond. Front. Oncol., 3.","DOI":"10.3389\/fonc.2013.00324"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1088\/0031-9155\/56\/3\/012","article-title":"Renal Uptake of Bismuth-213 and Its Contribution to Kidney Radiation Dose Following Administration of Actinium-225-Labeled Antibody","volume":"56","author":"Schwartz","year":"2011","journal-title":"Phys. Med. Biol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1524\/ract.1993.60.1.1","article-title":"The Chemical Fate of 212Bi-DOTA Formed by Beta-Decay of 212Pb(DOTA)2","volume":"60","author":"Mirzadeh","year":"1993","journal-title":"Radiochim. Acta"},{"key":"ref_90","first-page":"1","article-title":"Preparation of 212Pb-Labeled Monoclonal Antibody Using a Novel 224Ra-Based Generator Solution","volume":"51","author":"Generalov","year":"2017","journal-title":"Nucl. Med. Biol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1158\/0008-5472.CAN-04-3096","article-title":"Efforts to Control the Errant Products of a Targeted In Vivo Generator","volume":"65","author":"Jaggi","year":"2005","journal-title":"Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1158\/0008-5472.CAN-10-1186","article-title":"Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN)","volume":"71","author":"Wild","year":"2011","journal-title":"Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.apradiso.2013.12.008","article-title":"Retention Studies of Recoiling Daughter Nuclides of 225Ac in Polymer Vesicles","volume":"85","author":"Wang","year":"2014","journal-title":"Appl. Radiat. Isot."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1088\/0031-9155\/52\/16\/021","article-title":"Treatment of Solid Tumors by Interstitial Release of Recoiling Short-Lived Alpha Emitters","volume":"52","author":"Arazi","year":"2007","journal-title":"Phys. Med. Biol."},{"key":"ref_95","first-page":"137","article-title":"Pharmacokinetic Variability 225Ac and 213Bi from Vector Labeled 225Ac Cancer Therapy as a Function of Vector Type (Antibody vs. Small Molecule)","volume":"59","author":"Josefsson","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1007\/s00259-024-06681-2","article-title":"Image-Based Dosimetry for [225Ac]Ac-PSMA-I&T Therapy and the Effect of Daughter-Specific Pharmacokinetics","volume":"51","author":"Liubchenko","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Albertsson, P., Back, T., Bergmark, K., Hallqvist, A., Johansson, M., Aneheim, E., Lindegren, S., Timperanza, C., Smerud, K., and Palm, S. (2023). Astatine-211 Based Radionuclide Therapy: Current Clinical Trial Landscape. Front. Med., 9.","DOI":"10.3389\/fmed.2022.1076210"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.nucmedbio.2012.09.007","article-title":"Options to Meet the Future Global Demand of Radionuclides for Radionuclide Therapy","volume":"40","author":"Das","year":"2013","journal-title":"Nucl. Med. Biol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Miederer, M., Bene\u0161ov, M., Mamat, C., K\u00e4stner, D., Pretze, M., Michler, E., Brogsitter, C., Kotzerke, J., Kopka, K., and Scheinberg, D.A. (2024). Alpha-Emitting Radionuclides: Current Status and Future Perspectives. Pharmaceuticals, 17.","DOI":"10.3390\/ph17010076"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2174\/1874471011666180418141357","article-title":"The Production of Ac-225","volume":"11","author":"Engle","year":"2018","journal-title":"Curr. Radiopharm."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2174\/1874471011666180515123848","article-title":"NorthStar Perspectives for Actinium-225 Production at Commercial Scale","volume":"11","author":"Harvey","year":"2018","journal-title":"Curr. Radiopharm."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2967\/jnumed.120.251983","article-title":"Comparison of CD38-Targeted a-Versus b-Radionuclide Therapy of Disseminated Multiple Myeloma in an Animal Model","volume":"62","author":"Minnix","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Ferreira, C.A., Potluri, H.K., Mahmoudian, M., Massey, C.F., Grudzinski, J.J., Carston, A.M., Clemons, N.B., Idrissou, M.B., Thickens, A.S., and Rosenkrans, Z.T. (2025). Immunomodulatory Effects of Alpha vs Beta Radiopharmaceutical Therapy in Murine Prostate Cancer. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1563387"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Graf, F., Fahrer, J., Maus, S., Morgenstern, A., Bruchertseifer, F., Venkatachalam, S., Fottner, C., Weber, M.M., Huelsenbeck, J., and Schreckenberger, M. (2014). DNA Double Strand Breaks as Predictor of Efficacy of the Alpha-Particle Emitter Ac-225 and the Electron Emitter Lu-177 for Somatostatin Receptor Targeted Radiotherapy. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0088239"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"8941","DOI":"10.1158\/0008-5472.CAN-09-1828","article-title":"Radioimmunotherapy of Breast Cancer Metastases with \u03b1-Particle Emitter 225Ac: Comparing Efficacy with 213Bi and 90Y","volume":"69","author":"Song","year":"2009","journal-title":"Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1007\/s00259-014-2857-9","article-title":"213Bi-DOTATOC Receptor-Targeted Alpha-Radionuclide Therapy Induces Remission in Neuroendocrine Tumours Refractory to Beta Radiation: A First-in-Human Experience","volume":"41","author":"Kratochwil","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"S630","DOI":"10.1016\/j.annonc.2025.08.1601","article-title":"Safety, Tolerability and Efficacy of 212Pb-DOTAMTATE as a Targeted Alpha Therapy for Subjects with Unresectable or Metastatic Somatostatin Receptor-Expressing Gastroenteropancreatic Neuroendocrine Tumors (SSTR + GEP-NETs): A Phase 2 Study","volume":"36","author":"Strosberg","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"205004","DOI":"10.1088\/1361-6560\/ad7b9a","article-title":"Dosimetry at Cellular Level for the Alpha-Emitting Radionuclides Actinium-225, Astatine-211 and Radium-223 for Bone Metastasis Cells from Castration Resistant Prostate Cancer","volume":"69","author":"Maillard","year":"2024","journal-title":"Phys. Med. Biol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.2967\/jnumed.114.153502","article-title":"Monte Carlo Evaluation of Auger Electron\u2013Emitting Theranostic Radionuclides","volume":"56","author":"Falzone","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1118\/1.2963993","article-title":"119Sb\u2014A Potent Auger Emitter for Targeted Radionuclide Therapy","volume":"35","author":"Thisgaard","year":"2008","journal-title":"Med. Phys."},{"key":"ref_111","unstructured":"Saha, G.B. (2013). Fundamentals of Nuclear Pharmacy, Springer Nature."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrclinonc.2011.160","article-title":"Clinical Radioimmunotherapy-the Role of Radiobiology","volume":"8","author":"Pouget","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1524\/ract.1993.61.1.9","article-title":"Decay Studies of 197Tl (2.84 H) and 197mHg (23.8 H)","volume":"61","author":"Chakravarty","year":"1993","journal-title":"Radiochim. Acta"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1088\/0031-9155\/41\/10\/009","article-title":"Targeted Radiotherapy Using Auger Electron Emitters","volume":"41","author":"Wheldon","year":"1996","journal-title":"Phys. Med. Biol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.apradiso.2010.07.019","article-title":"Medium to Large Scale Radioisotope Production for Targeted Radiotherapy Using a Small PET Cyclotron","volume":"69","author":"Thisgaard","year":"2011","journal-title":"Appl. Radiat. Isot."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nucmedbio.2020.12.001","article-title":"Potent Candidates for Targeted Auger Therapy: Production and Radiochemical Considerations","volume":"94\u201395","author":"Filosofov","year":"2021","journal-title":"Nucl. Med. Biol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2307\/3575714","article-title":"Lethality of Auger Electrons from the Decay of Bromine-77 in the DNA of Mammalian Cells","volume":"90","author":"Kassis","year":"1982","journal-title":"Radiat. Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2307\/3574422","article-title":"The Radiotoxicity of Iodine-125 in Mammalian Cells: II. A Comparative Study on Cell Survival and Cytogenetic Responses to 125IUdR, 131IUdR, and 3HTdR","volume":"67","author":"Chan","year":"1976","journal-title":"Radiat. Res."},{"key":"ref_119","first-page":"2196","article-title":"Radiotoxicity of Some Iodine-123, Iodine-125 and Iodine-131-Labeled Compounds in Mouse Testes: Implications for Radiopharmaceutical Design","volume":"33","author":"Narra","year":"1992","journal-title":"J. Nucl. Med."},{"key":"ref_120","unstructured":"Adelstein, S.J., Bloomer, W.D., Kassis, A.I., and Sastry, K.S.R. (1986). Nuclear Medicine in Clinical Oncology, Springer."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/hyb.1995.14.111","article-title":"Epidermal Growth Factor Receptor 425 Monoclonal Antibodies Radiolabeled with Iodine-125 in the Adjuvant Treatment of High-Grade Astrocytomas","volume":"14","author":"Snelling","year":"1995","journal-title":"Hybridoma"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0969-8051(93)90105-4","article-title":"Therapy with 125I-Labelled Internalized and Non-Internalized Monoclonal Antibodies in Nude Mice with Human Colon Carcinoma Xenografts","volume":"20","author":"Aronsson","year":"1993","journal-title":"Nucl. Med. Biol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2307\/3575480","article-title":"Radiotoxicity of 75Se and 35S: Theory and Application to a Cellular Model","volume":"84","author":"Kassis","year":"1980","journal-title":"Radiat. Res."},{"key":"ref_124","first-page":"174","article-title":"Therapeutic Radionuclides: Production and Decay Property Considerations","volume":"32","author":"Volkert","year":"1991","journal-title":"J. Nucl. Med."},{"key":"ref_125","first-page":"1479","article-title":"Cancer Therapy with Auger Electrons: Are We Almost There?","volume":"44","author":"Kassis","year":"2003","journal-title":"J. Nucl. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3109\/09553002.2014.892649","article-title":"Fast Monte Carlo Simulation of DNA Damage Induction by Auger-Electron Emission","volume":"90","author":"Hsiao","year":"2014","journal-title":"Int. J. Radiat. Biol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2307\/3576987","article-title":"Radiotoxicity of 125I in Mammalian Cells","volume":"111","author":"Kassis","year":"2015","journal-title":"Radiat. Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1667\/RR1359.1","article-title":"Cell Membrane Is a More Sensitive Target than Cytoplasm to Dense Ionization Produced by Auger Electrons","volume":"170","author":"Pouget","year":"2008","journal-title":"Radiat. Res."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Knapp, F.F., and Dash, A. (2016). Auger Electron-Based Radionuclide Therapy. Radiopharmaceuticals for Therapy, Springer.","DOI":"10.1007\/978-81-322-2607-9"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.2967\/jnumed.122.265039","article-title":"Marshalling the Potential of Auger Electron Radiopharmaceutical Therapy","volume":"64","author":"Bolcaen","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1088\/0031-9155\/55\/9\/009","article-title":"Monte Carlo Single-Cell Dosimetry of Auger-Electron Emitting Radionuclides","volume":"55","author":"Bousis","year":"2010","journal-title":"Phys. Med. Biol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.radphyschem.2017.01.028","article-title":"Dosimetry Assessment of DNA Damage by Auger-Emitting Radionuclides: Experimental and Monte Carlo Studies","volume":"140","author":"Belchior","year":"2017","journal-title":"Radiat. Phys. Chem."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2967\/jnumed.117.207308","article-title":"Targeting Micrometastases: The Effect of Heterogeneous Radionuclide Distribution on Tumor Control Probability","volume":"60","author":"Falzone","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/BF02426701","article-title":"Radionuclide Targeting and Dosimetry at the Microscopic Level: The Role of Microautoradiography","volume":"21","author":"Puncher","year":"1994","journal-title":"Eur. J. Nucl. Med."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Bavelaar, B.M., Lee, B.Q., Gill, M.R., Falzone, N., and Vallis, K.A. (2018). Subcellular Targeting of Theranostic Radionuclides. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00996"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.nimb.2015.11.008","article-title":"Complex Cell Geometry and Sources Distribution Model for Monte Carlo Single Cell Dosimetry with Iodine 125 Radioimmunotherapy","volume":"366","author":"Arnaud","year":"2016","journal-title":"Nucl. Instrum. Methods Phys. Res. B"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12967-023-03991-1","article-title":"Large-Scale In Vitro Microdosimetry via Live Cell Microscopy Imaging: Implications for Radiosensitivity and RBE Evaluations in Alpha-Emitter Radiopharmaceutical Therapy","volume":"21","author":"Bastiaannet","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.2967\/jnumed.121.263273","article-title":"Radiopharmaceutical Dosimetry for Cancer Therapy: From Theory to Practice","volume":"62","author":"Wahl","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.2967\/jnumed.121.262305","article-title":"Dosimetry in Radiopharmaceutical Therapy","volume":"63","author":"Zanzonico","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_140","first-page":"12S","article-title":"Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns","volume":"62","author":"Sgouros","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_141","first-page":"1965","article-title":"MIRD Pamphlet No. 31: MIRDcell V4\u2014Artificial Intelligence Tools to Formulate Optimized Radiopharmaceutical Cocktails for Therapy","volume":"65","author":"Katugampola","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.2967\/jnumed.121.262749","article-title":"Dosimetry for Radiopharmaceutical Therapy: Current Practices and Commercial Resources","volume":"62","author":"Capala","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Sharma, S., and Pandey, M.K. (2023). Radiometals in Imaging and Therapy: Highlighting Two Decades of Research. Pharmaceuticals, 16.","DOI":"10.3390\/ph16101460"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Khalil, M.M. (2016). Basic Science of PET Imaging, Springer International Publishing.","DOI":"10.1007\/978-3-319-40070-9"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2011.06077.x","article-title":"Fundamentals of PET and PET\/CT Imaging","volume":"1228","author":"Basu","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2967\/jnumed.116.184028","article-title":"Total-Body PET: Maximizing Sensitivity to Create New Opportunities for Clinical Research and Patient Care","volume":"59","author":"Cherry","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"eaaf6169","DOI":"10.1126\/scitranslmed.aaf6169","article-title":"Total-Body Imaging: Transforming the Role of Positron Emission Tomography","volume":"9","author":"Cherry","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Khalil, M.M. (2021). Basic Sciences of Nuclear Medicine, Springer Nature.","DOI":"10.1007\/978-3-030-65245-6"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"796025","DOI":"10.1155\/2011\/796025","article-title":"Molecular SPECT Imaging: An Overview","volume":"2011","author":"Khalil","year":"2011","journal-title":"Int. J. Mol. Imaging"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Borgna, F., Barritt, P., Grundler, P.V., Talip, Z., Cohrs, S., Zeevaart, J.R., K\u00f6ster, U., Schibli, R., van der Meulen, N.P., and M\u00fcller, C. (2021). Simultaneous Visualization of 161Tb-and 177Lu-Labeled Somatostatin Analogues Using Dual-Isotope SPECT Imaging. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13040536"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"235029","DOI":"10.1088\/1361-6560\/aaef63","article-title":"Dual SPECT Imaging of 111In and 67Ga to Simultaneously Determine in Vivo the Pharmacokinetics of Different Radiopharmaceuticals: A Quantitative Tool in Pre-Clinical Research","volume":"63","author":"Esquinas","year":"2018","journal-title":"Phys. Med. Biol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1084\/jem.103.5.653","article-title":"Action of X-Rays on Mammalian Cells","volume":"103","author":"Puck","year":"1956","journal-title":"J. Exp. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1038\/nprot.2006.339","article-title":"Clonogenic Assay of Cells In Vitro","volume":"1","author":"Franken","year":"2006","journal-title":"Nat. Protoc."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"5623235","DOI":"10.1155\/2016\/5623235","article-title":"A Systematic Comparison Identifies an ATP-Based Viability Assay as Most Suitable Read-Out for Drug Screening in Glioma Stem-Like Cells","volume":"2016","author":"Kleijn","year":"2016","journal-title":"Stem Cells Int."},{"key":"ref_155","first-page":"129","article-title":"Comparison of Chemosensitivity Tests: Clonogenic Assay versus MTT Assay","volume":"56","author":"Kawada","year":"2002","journal-title":"Acta Med. Okayama"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1748-717X-7-1","article-title":"Determination of Cell Survival after Irradiation via Clonogenic Assay versus Multiple MTT Assay\u2014A Comparative Study","volume":"7","author":"Buch","year":"2012","journal-title":"Radiat. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0006-291X(84)90411-X","article-title":"Microelectrophoreticstudy of Radiation-Induced DNA Damages in Individual Mammalian Cells","volume":"123","author":"Ostling","year":"1984","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_158","unstructured":"OCED (2016). Test No. 489: In Vivo Mammalian Alkaline Comet Assay. OECD Guidelines for the Testing of Chemicals, OECD Publishing."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0165-1110(94)00013-3","article-title":"The Comet Assay: A Comprehensive Review","volume":"339","author":"Fairbairn","year":"1995","journal-title":"Mutat. Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/mutage\/gem051","article-title":"The Comet Assay: Topical Issues","volume":"23","author":"Collins","year":"2008","journal-title":"Mutagenesis"},{"key":"ref_161","first-page":"1","article-title":"The Comet Assay: Ready for 30 More Years","volume":"33","year":"2018","journal-title":"Mutagenesis"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1074\/jbc.273.10.5858","article-title":"DNA Double-Stranded Breaks Induce Histone H2AX Phosphorylation on Serine 139","volume":"273","author":"Rogakou","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/leu.2010.6","article-title":"\u0393h2AX: A Sensitive Molecular Marker of DNA Damage and Repair","volume":"24","author":"Mah","year":"2010","journal-title":"Leukemia"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1093\/nar\/gkn550","article-title":"Gamma-H2AX in Recognition and Signaling of DNA Double-Strand Breaks in the Context of Chromatin","volume":"36","author":"Kinner","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"ref_165","first-page":"e56617","article-title":"Immunofluorescence Microscopy of \u0393H2AX and 53BP1 for Analyzing the Formation and Repair of DNA Double-Strand Breaks","volume":"129","author":"Popp","year":"2017","journal-title":"J. Vis. Exp."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Atkinson, J., Bezak, E., Le, H., and Kempson, I. (2024). DNA Double Strand Break and Response Fluorescent Assays: Choices and Interpretation. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25042227"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.molcel.2013.01.001","article-title":"A Cell Cycle-Dependent Regulatory Circuit Composed of 53BP1-RIF1 and BRCA1-CtIP Controls DNA Repair Pathway Choice","volume":"49","author":"Orthwein","year":"2013","journal-title":"Mol. Cell."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0968-0004(98)01232-8","article-title":"Role of the Human RAD51 Protein in Homologous Recombination and Double-Stranded-Break Repair","volume":"23","author":"Baumann","year":"1998","journal-title":"Trends Biochem. Sci."},{"key":"ref_169","unstructured":"Briesmeister, J. (1986). MCNP\u2014A General Monte Carlo Code for Neutron and Photon Transport, Los Alamos National Laboratory. Version SA Rep. LA-7396-M."},{"key":"ref_170","unstructured":"Kawrakow, I., and Rogers, D.W.O. (2025). The EGSnrc Code System: Monte Carlo Simulation of Electron and Photon Transport, National Research Council Canada. NRCC Report PIRS-701."},{"key":"ref_171","unstructured":"Salvat, F. (2015). PENELOPE-2014: A Code System for Monte Carlo Simulation of Electron and Photon Transport, Nuclear Energy Agency."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"07251","DOI":"10.1118\/1.4810963","article-title":"JADA: A Graphical User Interface for Comprehensive Internal Dose Assessment in Nuclear Medicine","volume":"40","author":"Grimes","year":"2013","journal-title":"Med. Phys."},{"key":"ref_173","first-page":"301","article-title":"Implementation and Evaluation of Patient-Specific Three-Dimensional Internal Dosimetry","volume":"38","author":"Kolbert","year":"1997","journal-title":"J. Nucl. Med."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.radphyschem.2014.01.002","article-title":"Development and Validation of a Fast Voxel-Based Dose Evaluation System in Nuclear Medicine","volume":"104","author":"Lu","year":"2014","journal-title":"Radiat. Phys. Chem."},{"key":"ref_175","first-page":"662","article-title":"Monte Carlo MCNP-4B-Based Absorbed Dose Distribution Estimates for Patient-Specific Dosimetry","volume":"42","author":"Yoriyaz","year":"2001","journal-title":"J. Nucl. Med."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1088\/0031-9155\/58\/8\/2491","article-title":"Development and Validation of RAYDOSE: A Geant4-Based Application for Molecular Radiotherapy","volume":"58","author":"Marcatili","year":"2013","journal-title":"Phys. Med. Biol."},{"key":"ref_177","first-page":"840","article-title":"Accurate Dosimetry in 131I Radionuclide Therapy Using Patient-Specific, 3-Dimensional Methods for SPECT Reconstruction and Absorbed Dose Calculation","volume":"46","author":"Dewaraja","year":"2005","journal-title":"J. Nucl. Med."},{"key":"ref_178","first-page":"155","article-title":"Development and Validation of RAPID: A Patient-Specific Monte Carlo Three-Dimensional Internal Dosimetry Platform","volume":"33","author":"Besemer","year":"2018","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_179","first-page":"325","article-title":"OEDIPE: A Personalized Dosimetric Tool Associating Voxel-Based Models with MCNPX","volume":"20","author":"Chiavassa","year":"2005","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_180","unstructured":"Stelson, A., Stabin, M., and Sparks, R. (1999). The SIMDOS Monte Carlo Code for Conversion of Activity Distributions to Absorbed Dose and Dose-Rate Distributions. Sixth International Radiopharmaceutical Dosimetry Symposium, Gatlinburg, TN, USA, 7\u201310 May 1997, Oak Ridge Associated Universities."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.semradonc.2023.03.011","article-title":"Theranostics and Patient-Specific Dosimetry","volume":"33","author":"Bednarz","year":"2023","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.semradonc.2020.07.008","article-title":"Dosimetry for Optimized, Personalized Radiopharmaceutical Therapy","volume":"31","author":"Graves","year":"2020","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_183","first-page":"11102","article-title":"Monte Carlo Simulation in Radionuclide Therapy Dosimetry","volume":"15","author":"Maria","year":"2019","journal-title":"Biomed. J. Sci. Tech. Res."},{"key":"ref_184","first-page":"3S","article-title":"The MIRD Perspective 1999","volume":"40","author":"Howell","year":"1999","journal-title":"J. Nucl. Med."},{"key":"ref_185","unstructured":"Bartlett, R.M., Bolch, W.E., Bertrand Brill, A., Dewaraja, Y.K., Fahey, F.H., Fisher, D.R., Hobbs, R.F., Howell, R.W., Meredith, R.F., and Rajendran, J.G. (2022). The MIRD Primer 2022: A Complete Guide to Radiopharmaceutical Dosimetry, Society of Nuclear Medicine and Molecular Imaging."},{"key":"ref_186","unstructured":"(2026, January 15). SNMMI MIRD Committee. MIRDsoft. Available online: https:\/\/mirdsoft.org\/."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/HP.0000000000001682","article-title":"OLINDA\/EXM 2\u2014The Next-Generation Personal Computer Software for Internal Dose Assessment in Nuclear Medicine","volume":"124","author":"Stabin","year":"2023","journal-title":"Health Phys."},{"key":"ref_188","first-page":"1023","article-title":"OLINDA\/EXM: The Second-Generation Personal Computer Software for Internal Dose Assessment in Nuclear Medicine","volume":"46","author":"Stabin","year":"2005","journal-title":"J. Nucl. Med."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2967\/jnmt.123.265668","article-title":"The MIRD Schema for Radiopharmaceutical Dosimetry: A Review","volume":"52","author":"Zanzonico","year":"2024","journal-title":"J. Nucl. Med. Technol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/4\/591\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T07:38:16Z","timestamp":1775633896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/4\/591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":189,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["ph19040591"],"URL":"https:\/\/doi.org\/10.3390\/ph19040591","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]}}}